ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,341 to 1,360 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
aQIV vs Non-influenza Comparator Vaccine: deaths from any cause33 of 3,380

34 of 3,377

-0.0 points

-0.5 to 0.5

6,757NCT02587221

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

aQIV vs Non-influenza Comparator Vaccine: serious adverse events238 of 3,380

234 of 3,377

0.1 points

-1.1 to 1.3

6,757NCT02587221

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Immediate Return of Results (Intent to Treat, ITT) vs Delayed Return of Results (Intent to Treat, ITT): deaths from any cause13 of 3,380

12 of 3,374

0.0 points

-0.3 to 0.3

6,754NCT04191824

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States

Intervention: Diagnostic Algorithm vs Usual Care: Additional Investigations at Index Consultation and/or During Follow-up335 of 2,988

517 of 3,762

-2.5 points

-4.1 to -0.9

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Clinical Recovery at Day 302,967 of 2,988

3,747 of 3,762

-0.3 points

-0.7 to 0.1

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Admission to Hospital at Day 07 of 2,988

11 of 3,762

-0.1 points

-0.3 to 0.2

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Additional Testing at Index Consultation249 of 2,988

400 of 3,762

-2.3 points

-3.7 to -0.9

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Admission to Hospital During Follow-up25 of 2,988

53 of 3,762

-0.6 points

-1.1 to -0.1

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Referral to Hospital at Day 024 of 2,988

13 of 3,762

0.5 points

0.1 to 0.9

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Additional Testing During Follow-up111 of 2,988

149 of 3,762

-0.2 points

-1.2 to 0.7

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Referral to Hospital During Follow-up79 of 2,988

84 of 3,762

0.4 points

-0.3 to 1.2

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Re-consultation During Follow-up770 of 2,988

968 of 3,762

0.0 points

-2.1 to 2.1

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Clinical Recovery at Day 72,539 of 2,988

3,200 of 3,762

-0.1 points

-1.8 to 1.6

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Antibiotic Prescribing Rate During Follow-up291 of 2,988

429 of 3,762

-1.7 points

-3.1 to -0.2

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Intervention: Diagnostic Algorithm vs Usual Care: Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed)466 of 2,988

817 of 3,762

-6.1 points

-8.0 to -4.3

6,750NCT04470518

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With Solicited Local Adverse Events (AEs) During 7 Days Following Vaccination (Double Blind Phase)1,839 of 3,356

684 of 3,379

34.6 points

32.4 to 36.7

6,735NCT04505722

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With Unsolicited AEs During 28 Days Post-vaccination (Double Blind Phase)456 of 3,356

422 of 3,379

1.1 points

-0.5 to 2.7

6,735NCT04505722

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With Solicited Systemic AEs During 7 Days Following Vaccination (Double Blind Phase)2,021 of 3,356

1,307 of 3,379

21.5 points

19.2 to 23.9

6,735NCT04505722

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

ProQuad® Arm: Dose 2 vs ProQuad® Arm: Dose 1: serious adverse events22 of 3,342

40 of 3,376

-0.5 points

-1.0 to -0.1

6,718NCT00560755

Safety Study of ProQuad® rHA in Infants (V221-037)

Palivizumab vs Motavizumab: Incidence of RSV Hospitalization (Includes Deaths by RSV)62 of 3,306

46 of 3,329

0.5 points

-0.1 to 1.1

6,635NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=68

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02587221-deaths",
        "title": "aQIV vs Non-influenza Comparator Vaccine: deaths from any cause",
        "summary": "33 of 3380 against 34 of 3377; risk difference -0.0 points, 95% interval -0.5 to 0.5; NCT02587221, Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age",
        "record": "/library/comparisons/NCT02587221-deaths",
        "nct_id": "NCT02587221",
        "kind": "deaths",
        "participants": 6757,
        "risk_difference": {
          "value": -0.0003047941785100407,
          "lower": -0.005162549695794483,
          "upper": 0.0045409157067476365
        },
        "group_1": "33 of 3,380",
        "group_2": "34 of 3,377",
        "difference": "-0.0 points",
        "interval": "-0.5 to 0.5",
        "trial_title": "Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age"
      },
      {
        "id": "NCT02587221-sae",
        "title": "aQIV vs Non-influenza Comparator Vaccine: serious adverse events",
        "summary": "238 of 3380 against 234 of 3377; risk difference 0.1 points, 95% interval -1.1 to 1.3; NCT02587221, Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age",
        "record": "/library/comparisons/NCT02587221-sae",
        "nct_id": "NCT02587221",
        "kind": "serious-adverse-events",
        "participants": 6757,
        "risk_difference": {
          "value": 0.0011219299367632996,
          "lower": -0.011064578411532211,
          "upper": 0.013310821606576234
        },
        "group_1": "238 of 3,380",
        "group_2": "234 of 3,377",
        "difference": "0.1 points",
        "interval": "-1.1 to 1.3",
        "trial_title": "Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=69",
  "request_id": "UIBMk0srp3_sFryW"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?